



24th August 2021

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai 400 001

The Secretary
The National Stock Exchange of India
Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra East,
Mumbai 400 050

Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

Dear Sirs

The unaudited financial results of the Company for the quarter and half year ended 30th June 2021 were approved by the Board of Directors of the Company at its meeting held on 27th July 2021 and published on 29th July 2021. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 30th June 2021 in the format specified in the applicable accounting standards.

Kindly take the above information on record.

Thanking you,

Yours faithfully

For SANOFI INDIA LIMITED

A handwritten signature in blue ink, appearing to read "Girish Tekchandani", written over a horizontal line.

GIRISH TEKCHANDANI
COMPANY SECRETARY

Related Party Disclosures**i. Parties where control exists:**

- a) Sanofi S.A. France, ultimate holding Company
- b) Hoechst GmbH, Germany, holding Company

ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the period.

Sanofi-Aventis Singapore Pte. Limited
 Francopia S.A.R.L.
 Sanofi-Aventis Deutschland GmbH
 Sanofi Lanka Limited
 Sanofi-aventis Philippines Inc.
 Sanofi-Aventis Geston SA
 Sanofi Winthrop Industrie S.A.
 Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited) **
 Sanofi Chimie S.A
 Sanofi-aventis Healthcare Pty Ltd
 Sanofi-Aventis Vietnam Company Limited
 Sanofi India Limited Provident Fund

iii. Key management personnel of the Company for the year

Mr. Rajaram Narayanan - Managing Director
 Mr. Cherian Mathew - Whole Time Director
 Mr. Vaibhav Karandikar - Chief Financial officer (w.e.f October 06, 2020) and Whole time director (w.e.f February 23, 2021)
 Mr. Girish Tekchandani - Company Secretary

iv. Non-Executive Directors

Mr. Cyril Grandchamp-Desraux
 Mr. Marc-Antoine Lucchini
 Mr. Charles Billard

v. Independent Directors

Mr. Aditya Narayan
 Mrs. Usha Thorat
 Mr. Rahul Bhatnagar

vi. Transactions during the year

(₹ in Million)

Particulars	June 30, 2021
Ultimate Holding Company	
Dividend paid	2
Holding Company	
Dividend paid	5,075
Other related Parties	
Sale of Products	
Sanofi-Aventis Singapore Pte. Limited	1,869
Others	92
Total	1,961
Purchase of Raw Materials and Traded Goods	
Sanofi-Aventis Singapore Pte. Limited	2,127
Sanofi Healthcare India Private Limited**	1,094
Others	543
Total	3,764
Expenses recharged to other companies	
Sanofi-aventis Philippines Inc.	*
Sanofi Healthcare India Private Limited**	7
Total	7
Sale of Services	
Sanofi Healthcare India Private Limited**	631
Others	48
Total	679
Rent Income	
Sanofi Healthcare India Private Limited**	*
Total	*
Rent Paid	
Sanofi Healthcare India Private Limited **	*
Total	*
Loans Repaid	
Sanofi Healthcare India Private Limited**	50
Loans given	
Sanofi Healthcare India Private Limited **	50
Interest income on loans	
Sanofi Healthcare India Private Limited**	147
Total	147

(₹ in Million)

Particulars	June 30, 2021
Expenses recharged by other companies	
Sanofi Healthcare India Private Limited**	22
Total	22
Contribution to In-house Trust for Post Employment Benefits - Provident Fund	
Sanofi India Limited Provident Fund #	164
Payment towards Intangibles under development	
Sanofi Healthcare India Private Limited**	11
Key Management Personnel Remuneration	
Remuneration	
Mr. Rajaram Narayanan	21
Mr. Cherian Mathew	13
Mr. Vaibhav Karandikar	8
Mr. Girish Tekchandani	7
Total	49
Share based benefit	
Mr. Rajaram Narayanan	4
Mr. Cherian Mathew	2
Mr. Vaibhav Karandikar	1
Total	7
Sitting Fees to Independent Directors	
Mr. Aditya Narayan	*
Ms. Usha Thorat	*
Mr. Rahul Bhatnagar	*
Total	1
Commission to Independent Directors ##	
Mr. Aditya Narayan	1
Ms. Usha Thorat	*
Mr. Rahul Bhatnagar	*
Total	2

* denotes figure less than a million

Including contribution by employees.

Provisions made for half year ended 30th June 2021

Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year six month ended June 30, 2021, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

vii. Outstanding as at June 30, 2021

(₹ in Million)

Particulars	June 30, 2021
Other related Parties :	
Trade Receivables	
Sanofi-Aventis Singapore Pte. Limited	433
Sanofi Healthcare India Private Limited **	84
Others	56
Total	573
Trade Payables	
Sanofi-Aventis Singapore Pte. Limited	817
Sanofi Healthcare India Private Limited**	466
Francopia S.A.R.L.	536
Others	204
Total	2,023
Others Payables	
Sanofi Healthcare India Private Limited**	244
Total	244
Loans receivable	
Sanofi Healthcare India Private Limited # **	4,450
Total	4,450

#Loans given to Sanofi Healthcare India Private Limited at the rate of interest of 7.5% p.a. (5.5 % w.e.f April 15, 2021)

Maximum balance outstanding during the year ₹ 4,500 Million

The said loans have been proposed to be utilized by Sanofi Healthcare India Private Limited for business purpose.

The Loans have been given against corporate guarantee by Sanofi S.A. (Ultimate Holding Company. The Maturity Date of same is April 15, 2022).

** Including entities Sanofi Synthelabo (India) Private Limited and Sanofi Pasteur India Private Limited which merged with Sanofi Healthcare India Private Limited with effect from June 1, 2021. The appointed date for the said merger is April 1, 2019.